Late Monday, Vertex Pharmaceuticals (VRTX) reported adjusted earnings of $4.20 per share on $2.52 billion in fourth-quarter sales. VRTX stock edged higher in late trades.

X

On average, analysts surveyed by FactSet expected the biotech company to earn $4.07 a share on $2.51 billion in sales.

During the year-earlier period, Vertex earned $3.76 per share and reported $2.3 billion in sales.

For the year, Vertex guided to $10.55 billion to $10.75 billion in product sales. VRTX stock analysts forecasted earnings of $15.03 per share and $9.86 billion in sales.

Vertex also announced positive results from its next-generation triple-drug regimen for cystic fibrosis. After 24 weeks of improvement, patients in two studies showed improvement in their ability to forcefully exhale for one second. This is a key test of lung function in cystic fibrosis patients. The new drug proved it’s not inferior to Vertex’s existing triple-approach, Trikafta.

In after-hours trading on today’s stock market, VRTX stock advanced fractionally to 430.50. Shares broke out of a flat base with a buy point at 387.42, according to MarketSmith.com. Now, shares are trading above the buy zone. Vertex is also an IBD Tech Leader.

More to follow.

Follow Allison Gatlin on X, the platform formerly known as Twitter, at @IBD_AGatlin.

YOU MAY ALSO LIKE:

AbbVie Expects Two Of Its Biggest Drugs To Bring In $27 Billion In 2027. And Neither One Is Humira.

Bristol Myers Stock Yo-Yoes, Trying To Avoid A Fourth Day In The Red, On So-So Earnings

How To Research Growth Stocks: Why This IBD Tool Simplifies The Search For Top Stocks

Watch IBD’s Investing Strategies Show For Actionable Market Insights

Join IBD Live For Stock Ideas Each Morning Before The Open